Research of the value of high risk HPV DNA test combined with TCT in cervical cancer screening

Objective To discuss the clinical value of high risk HPV DNA combined with TCT in cervical cancer screening.Methods A total of 595 women received cervical cancer screening services in our hospital from January 2014 to January 2017 were selected. Among them, 300 women who received TCT test as the control group and 295 women who received high-risk human papillomavirus (HPV) DNA test combined with TCT as the observation group. The clinical values of different screening tests on cervical cancer screening were compared.Results The results of biopsy by colposcopy showed that the cervical lesions in the control group and the observation group were 51 cases and 49 cases, respectively. The detection rate of cervical lesions in the control group was 49.0% (25/51). The detection rate of cervical lesions in the observation group was 73.5% (36/49). The difference in the detection rate of cervical lesions between the two groups was statistically significant (P<0.05). The detection rate of cervical intraepithelial neoplasia (CIN) 2 + in the observation group and the control group was 44.9% (22/49) and 35.3% (18/51), respectively. The difference between the two groups was statistically significant (P<0.05). The detection rates of CIN2 + among women with positive results of HPV DNA test and TCT in the observation group were significantly higher than in control group. The detection rate of CIN1 among women with HPV DNA high load and negative results of TCT in observation group was significantly higher than that in control group.Conclusion The high risk HPVDNA test combined with TCT is helpful to improve the detection rate of cervical lesions.